Cardior Pharmaceuticals is at the forefront of developing innovative therapeutics that target heart disease through non-coding RNA (ncRNA) technology. Their lead compound, CDR132L, represents a groundbreaking approach as the first ncRNA-based therapy to enter clinical trials specifically for heart disease. This therapy is designed to address the adverse effects of myocardial infarction (MI) by reversing detrimental cardiac remodeling and restoring normal cellular functions in cardiac cells. Currently, CDR132L is being evaluated in the Phase 2 HF-REVERT clinical trial, which involves 280 patients across more than 60 locations in Europe, highlighting the company's commitment to advancing treatment options for heart failure.

The clinical trials conducted by Cardior Pharmaceuticals aim to provide effective solutions for heart failure, a condition that significantly impacts global health. The promising results from their Phase 1b study, published in the European Heart Journal, indicate a favorable safety profile and beneficial cardiac effects of CDR132L compared to placebo. This research underscores Cardior's dedication to pushing the boundaries of heart disease treatment and improving the quality of life for patients affected by this serious condition.

Germany

Cardior Pharmaceuticals is a leading clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. Cardior’s therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions. The company aspires to bring transformative therapeutics and diagnostics to patients and thereby make a lasting impact on the treatment of cardiac diseases worldwide.

Cardior Pharmaceuticals

Company Details